Product Description
Chlorphenamine is an antihistamine medicine that relieves the symptoms of allergies. It's known as a drowsy (sedating) antihistamine. This means that it is likely to make you feel more sleepy than some other antihistamines. It's used for: hay fever.
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Substance Abuse Unspecified | Animal Hypersensitivity | Environmental Hypersensitivity | Common Cold | Substance Abuse Unspecified | Common Cold
Known Adverse Events: Dizziness | Headache | Lethargy | Constipation | Tachycardia | Tachycardia, Ventricular | Tremor
Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Honduras
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACCROS-III | P3 |
Completed |
COVID-19 |
2023-01-19 |
|
| ACCROS-I | P3 |
Completed |
COVID-19 |
2022-03-11 |